Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2022-08-31 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice 2 pages 219.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment date of a director and the director's relevant interests in securities, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director's interests, matching the definition of Director's Dealing filings. Therefore, the document is classified as a Director's Dealing report.
2022-08-31 English
Non-Executive Director appointment and retirement 2 pages 147.4KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new non-executive director and the retirement of an existing director. It details the background of the new director, the retirement of the deputy chair, and includes quotes from the company chair. There is no financial data, no report or presentation attached, and the content focuses solely on changes in the company's board of directors. This fits the category of Board/Management Information (MANG). The document length is 3442 characters, which is consistent with a typical announcement rather than a full report.
2022-08-30 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of performance rights for Mayne Pharma Group Limited. It provides specific information about securities that have ceased, including the number, reason for cessation, and the impact on issued capital. The document is an announcement about changes in the company's issued securities, specifically the lapse of conditional rights, rather than a financial report or detailed analysis. It does not contain financial statements or management discussion, nor is it a report publication or certification. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities status changes that do not fit into more specific categories like share issues or director dealings.
2022-08-30 English
Appendix 4E and Statutory Accounts 76 pages 1.8MB
Annual Report Classification · 100% confidence The document is dated 26 August 2022 and is titled 'Preliminary Final Report and accompanying announcement' for the year ended 30 June 2022. It includes an Appendix 4E, Annual Financial Statements, Directors' Report, Remuneration Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes, Directors' Declaration, and Independent Auditor's Report. The content covers comprehensive financial performance, detailed financial statements, directors' information, and auditor's report for the full fiscal year ending 30 June 2022. This matches the characteristics of an Annual Report (10-K equivalent) which is a full yearly report covering company activity and full financial performance. The document length is substantial (15,000 characters), and it contains actual financial data and detailed analysis, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2022
2022-08-25 English
2022 Full Year Media Release 6 pages 388.9KB
Annual Report Classification · 95% confidence The document is a detailed announcement dated 26 August 2022 reporting the full fiscal year 2022 financial results of Mayne Pharma Group Limited. It includes comprehensive financial data such as revenues, EBITDA, net loss, segment performance, debt and cash flow details, and outlook commentary. The document also references the FY22 Results Presentation and an investor webcast. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis, not just a summary or announcement of a report. The content aligns with a full annual financial report rather than a brief earnings release or a simple announcement. Therefore, the document fits the definition of an Annual Report (10-K equivalent) rather than an Earnings Release or Report Publication Announcement. Hence, the classification is Annual Report (10-K). FY 2022
2022-08-25 English
2022 Full Year Investor Presentation 34 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is titled 'FY22 Results Presentation 26 August 2022' and is presented by the CEO and CFO of Mayne Pharma Group Limited. It contains detailed financial and strategic information including transaction summaries, capital management plans, product performance metrics, and forward-looking statements. The content is structured as a presentation aimed at investors, focusing on financial results, strategic updates, and market positioning rather than a formal annual report or regulatory filing. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER) which would be more concise. It is not an audit report, board change announcement, or legal proceeding update. The presence of slides, charts, and forward-looking statements aligns with an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-08-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.